ATE307600T1 - Verwendung von mycobacterium vaccae zur therapie des chronischen müdigkeitssyndrom - Google Patents

Verwendung von mycobacterium vaccae zur therapie des chronischen müdigkeitssyndrom

Info

Publication number
ATE307600T1
ATE307600T1 AT97949067T AT97949067T ATE307600T1 AT E307600 T1 ATE307600 T1 AT E307600T1 AT 97949067 T AT97949067 T AT 97949067T AT 97949067 T AT97949067 T AT 97949067T AT E307600 T1 ATE307600 T1 AT E307600T1
Authority
AT
Austria
Prior art keywords
therapy
chronic fatigue
fatigue syndrome
mycobacterium vaccae
vaccae
Prior art date
Application number
AT97949067T
Other languages
English (en)
Inventor
Graham Arthur William Rook
John Lawson Stanford
Alimuddin Ismail Zumla
Original Assignee
Stanford Rook Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9626215.9A external-priority patent/GB9626215D0/en
Priority claimed from GBGB9626859.4A external-priority patent/GB9626859D0/en
Application filed by Stanford Rook Ltd filed Critical Stanford Rook Ltd
Application granted granted Critical
Publication of ATE307600T1 publication Critical patent/ATE307600T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
AT97949067T 1996-12-18 1997-12-17 Verwendung von mycobacterium vaccae zur therapie des chronischen müdigkeitssyndrom ATE307600T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9626215.9A GB9626215D0 (en) 1996-12-18 1996-12-18 A therapeutic agent and its use
GBGB9626859.4A GB9626859D0 (en) 1996-12-24 1996-12-24 Medical treatment
PCT/GB1997/003460 WO1998026790A1 (en) 1996-12-18 1997-12-17 Mycobacterium vaccae for down-regulation of the th2 activity of the immune system

Publications (1)

Publication Number Publication Date
ATE307600T1 true ATE307600T1 (de) 2005-11-15

Family

ID=26310662

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97949067T ATE307600T1 (de) 1996-12-18 1997-12-17 Verwendung von mycobacterium vaccae zur therapie des chronischen müdigkeitssyndrom

Country Status (17)

Country Link
EP (1) EP0951289B1 (de)
JP (1) JP4358306B2 (de)
KR (1) KR100533818B1 (de)
CN (1) CN1129453C (de)
AP (1) AP1044A (de)
AT (1) ATE307600T1 (de)
AU (1) AU730548B2 (de)
BR (1) BR9713959A (de)
CA (1) CA2273848C (de)
DE (1) DE69734461T2 (de)
DK (1) DK0951289T3 (de)
ES (1) ES2251744T3 (de)
FI (1) FI120136B (de)
NO (1) NO321202B1 (de)
NZ (1) NZ336147A (de)
RU (1) RU2197989C2 (de)
WO (1) WO1998026790A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6361776B1 (en) * 1999-12-06 2002-03-26 Genesis Research & Development Corp. Ltd. Compounds isolated from M. vaccae and their use in modulation of immune responses
JP2003535903A (ja) * 2000-06-19 2003-12-02 ミューコプロテック・プロプライエタリー・リミテッド プロバイオティックを用いた、粘膜表面での細菌またはウイルス感染の免疫療法または治療、およびそのための組成物
AUPR101600A0 (en) * 2000-10-25 2000-11-16 Atheromastat Pty Ltd Compositions and methods for diagnosis and treatment of cardiovascular disorders
DE60235971D1 (de) 2001-02-20 2010-05-27 Maruho Kk Neue medizinische verwendung von alpha-antigen oder alpha-antigen-gen
RU2238558C2 (ru) * 2002-09-11 2004-10-20 Государственный НИИ курортологии Способ оценки функционального состояния больных синдромом хронической усталости
JP4662925B2 (ja) * 2003-04-23 2011-03-30 マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ 改善された効率を有する結核ワクチン
RU2318525C1 (ru) * 2006-06-29 2008-03-10 ГУ Научно-исследовательский институт фармакологии Томского научного центра Сибирского отделения Российской академии медицинских наук (ГУ НИИ фармакологии ТНЦ СО РАМН) СПОСОБ ПОЛУЧЕНИЯ ПОЛЯРИЗОВАННЫХ ЛИМФОЦИТОВ ДЛЯ МОДЕЛИРОВАНИЯ Th2-ИНДУЦИРОВАННОГО ОТЕКА
MX389834B (es) * 2015-06-24 2025-03-20 Immodulon Therapeutics Ltd Inhibidor del punto de regulacion y un mycobaterium de celula entera para uso en la terapia del cancer.
US11077179B2 (en) 2017-08-10 2021-08-03 Epicgenetics, Inc. Method for treating fibromyalgia and chronic fatigue syndrome

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL71683A0 (en) * 1984-04-27 1984-09-30 Yeda Res & Dev Pharmaceutical compositions for treating arthritis type diseases comprising fractions obtained from mycobacteria
GB9219425D0 (en) * 1992-09-14 1992-10-28 Univ London Therapeutic agent and its use
GB8919321D0 (en) * 1989-08-25 1989-10-11 Univ London Treatment of chronic inflammatory conditions
AU660430B2 (en) * 1990-11-08 1995-06-29 Stanford Rook Limited Mycobacterium as adjuvant for antigens
GB9203814D0 (en) * 1992-02-21 1992-04-08 Univ London Treatment of long term auto-immune conditions
GB9406301D0 (en) * 1994-03-30 1994-05-25 Univ London Immunotherapeutic agent and its use
AUPM864894A0 (en) * 1994-10-07 1994-11-03 Borody, Thomas Julius Treatment of bowel-dependent neurological disorders

Also Published As

Publication number Publication date
AP1044A (en) 2002-02-18
FI120136B (fi) 2009-07-15
KR100533818B1 (ko) 2005-12-07
JP2001506256A (ja) 2001-05-15
EP0951289A1 (de) 1999-10-27
HK1021316A1 (en) 2000-06-09
CA2273848C (en) 2008-02-19
NO992957L (no) 1999-08-10
NZ336147A (en) 2001-03-30
CN1129453C (zh) 2003-12-03
DE69734461D1 (de) 2005-12-01
BR9713959A (pt) 2000-04-11
ES2251744T3 (es) 2006-05-01
AP9901553A0 (en) 1999-06-30
AU7735598A (en) 1998-07-15
CN1246056A (zh) 2000-03-01
JP4358306B2 (ja) 2009-11-04
CA2273848A1 (en) 1998-06-25
WO1998026790A1 (en) 1998-06-25
DK0951289T3 (da) 2006-03-13
FI991384L (fi) 1999-06-17
KR20000069518A (ko) 2000-11-25
EP0951289B1 (de) 2005-10-26
AU730548B2 (en) 2001-03-08
NO321202B1 (no) 2006-04-03
RU2197989C2 (ru) 2003-02-10
FI991384A0 (fi) 1999-06-17
NO992957D0 (no) 1999-06-17
DE69734461T2 (de) 2006-07-06

Similar Documents

Publication Publication Date Title
BR9711530A (pt) Combina-Æo de terapia para tratamento de psicoses
ATA227794A (de) Beschlag zur höhenverstellung von schubladen
EE9900345A (et) Sulfonüülkarbamiidi ja glitasooni sünergistilised kombinatsioonid diabeedi raviks
DE59410125D1 (de) Gerät zur schmerztherapie und/oder zur beeinflussung des vegetativen nervensystems
DE69713295D1 (de) Azabicyclishe carbaniumsaureester zur therapeutsichen verwendung
DE69518919D1 (de) Autoantikörper enthaltende zusammensetzung für tumorbehandlung und -vorbeugung
NO963742D0 (no) Fremgangsmåte til å stimulere hematopoese med hemaglobin
NO983936L (no) Kombinasjonsterapi for osteporose
EP0723460A4 (de) Gentherapie für das nervensystems
PT752870E (pt) Utilizacao de mycobacterium para o tratamento de tumores
FI980246A7 (fi) Menetelmä keittimen käyttämiseksi ja keitin
DE59500266D1 (de) Transdermales therapeutisches System zur Applikation von Naloxon
DE69527471D1 (de) Plattensteuerung
DE69704855D1 (de) Induktionsheizgerät zur oberflächenbehandlung von zahnrädern
ATE307600T1 (de) Verwendung von mycobacterium vaccae zur therapie des chronischen müdigkeitssyndrom
NO983263D0 (no) Distribuert behandling
ID23175A (id) Penggunaan benzopiranol untuk mengobati gangguan syaraf
DE59711240D1 (de) Verwendung von flupirtin zur therapie und prophylaxe von myokardinfarkt, schockniere und schocklunge
NO984189D0 (no) Fremgangsmåte for behandling av bipolar forstyrrelse
DK0712472T3 (da) Gulvkonstruktion med flerkanalorganer
AU5374898A (en) The use of oxandrolone in the treatment of chronic fatigue syndrome
UA27998C2 (uk) Спосіб лікування гострого та хронічного міофасціального болю попереково-крижового відділу хребта
KR970004046U (ko) 수평상태를 조정할 수 있는 장농
BR7601412U (pt) Aparelho aplicável no tratamento de fluxo de graos em geral
FI971888A0 (fi) Ohjausaste

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0951289

Country of ref document: EP